Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for ...

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Those who own JNJ stock may stay invested for some time as the company looks optimistic about a better performance in 2025.

In the past year, shares of J&J have lost 7.3% compared with the industry’s decline of 5.1%. The latest FDA nod for Spravato was based on data from a double-blind, multicenter, placebo ...

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major depressive disorder (MDD) in adults who do not ...